GigaGen Studies Published in Peer-Reviewed Journal mAbs Validate Its Novel Monoclonal Antibody Discovery Approach in Mouse and Human Antibody Repertoires


GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming issue.

Read the full press release.